VISTAGEN THERAPEUTICS, INC. Comprehensive Income
VISTAGEN THERAPEUTICS, INC. (VTGN) reported Comprehensive Income of -$13.04 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:ComprehensiveIncomeNetOfTax · last filed 2026-08-14
- VISTAGEN THERAPEUTICS, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-06-30 was -$13.04M.
- VISTAGEN THERAPEUTICS, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-03-31 was -$16.29M.
- VISTAGEN THERAPEUTICS, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-12-31 was -$18.90M.
- VISTAGEN THERAPEUTICS, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-09-30 was -$19.40M.
- VISTAGEN THERAPEUTICS, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2026 was -$69.69M.
- VISTAGEN THERAPEUTICS, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2025 was -$51.41M.
- VISTAGEN THERAPEUTICS, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2024 was -$29.36M.
- VISTAGEN THERAPEUTICS, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2023 was -$59.25M.
| Period end | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 181 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 184 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | -$13.04M 10-Q · filed 2026-08-14 | -$29.32M derived: sum of 2 quarters · filed 2026-08-14 | -$48.22M derived: sum of 3 quarters · filed 2026-08-14 | -$67.63M derived: sum of 4 quarters · filed 2026-08-14 | ||
| 2026-03-31 | -$16.29M derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-15 | -$35.19M derived: sum of 2 quarters · filed 2026-06-15 | -$54.59M derived: sum of 3 quarters · filed 2026-06-15 | -$69.69M 10-K · filed 2026-06-15 | ||
| 2025-12-31 | -$18.90M 10-Q · filed 2026-02-12 | -$38.30M derived: sum of 2 quarters · filed 2026-02-12 | -$53.40M 10-Q · filed 2026-02-12 | -$67.04M derived: sum of 4 quarters · filed 2026-08-14 | ||
| 2025-09-30 | -$19.40M 10-Q · filed 2025-11-13 | -$34.50M 10-Q · filed 2025-11-13 | -$48.14M derived: sum of 3 quarters · filed 2026-08-14 | -$62.24M derived: sum of 4 quarters · filed 2026-08-14 | ||
| 2025-06-30 | -$15.10M 10-Q · filed 2026-08-14 | -$28.74M derived: sum of 2 quarters · filed 2026-08-14 | -$42.84M derived: sum of 3 quarters · filed 2026-08-14 | -$55.78M derived: sum of 4 quarters · filed 2026-08-14 | ||
| 2025-03-31 | -$13.64M derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-15 | -$27.74M derived: sum of 2 quarters · filed 2026-06-15 | -$40.68M derived: sum of 3 quarters · filed 2026-06-15 | -$51.41M 10-K · filed 2026-06-15 | ||
| 2024-12-31 | -$14.10M 10-Q · filed 2026-02-12 | -$27.04M derived: sum of 2 quarters · filed 2026-02-12 | -$37.77M 10-Q · filed 2026-02-12 | -$47.29M derived: sum of 4 quarters · filed 2026-02-12 | ||
| 2024-09-30 | -$12.94M 10-Q · filed 2025-11-13 | -$23.67M 10-Q · filed 2025-11-13 | -$33.19M derived: sum of 3 quarters · filed 2025-11-13 | -$39.54M derived: sum of 4 quarters · filed 2025-11-13 | ||
| 2024-06-30 | -$10.73M 10-Q · filed 2025-08-07 | -$20.25M derived: sum of 2 quarters · filed 2025-08-07 | -$26.60M derived: sum of 3 quarters · filed 2025-08-07 | -$33.19M derived: sum of 4 quarters · filed 2025-08-07 | ||
| 2024-03-31 | -$9.52M derived: 10-K 12 month − 10-Q 9 month · filed 2025-06-17 | -$15.87M derived: sum of 2 quarters · filed 2025-06-17 | -$22.46M derived: sum of 3 quarters · filed 2025-06-17 | -$29.36M 10-K · filed 2025-06-17 | ||
| 2023-12-31 | -$6.35M 10-Q · filed 2025-02-13 | -$12.94M derived: sum of 2 quarters · filed 2025-02-13 | -$19.84M 10-Q · filed 2025-02-13 | |||
| 2023-09-30 | -$6.59M 10-Q · filed 2024-11-07 | -$13.49M 10-Q · filed 2024-11-07 | ||||
| 2023-06-30 | -$6.90M 10-Q · filed 2024-08-13 | |||||
| 2023-03-31 | -$59.25M 10-K · filed 2024-06-11 | |||||
| 2016-12-31 | -$2.64M 10-Q · filed 2017-02-13 | -$5.74M derived: sum of 2 quarters · filed 2017-02-13 | -$7.71M 10-Q · filed 2017-02-13 | |||
| 2016-09-30 | -$3.10M 10-Q · filed 2016-11-14 | -$5.07M 10-Q · filed 2016-11-14 | ||||
| 2016-06-30 | -$1.97M 10-Q · filed 2016-08-12 | |||||
| 2015-12-31 | -$2.15M 10-Q · filed 2017-02-13 | -$9.19M derived: sum of 2 quarters · filed 2017-02-13 | -$38.72M 10-Q · filed 2017-02-13 | |||
| 2015-09-30 | -$7.05M 10-Q · filed 2016-11-14 | -$36.57M 10-Q · filed 2016-11-14 | ||||
| 2015-06-30 | -$29.52M 10-Q · filed 2016-08-12 | |||||
| 2014-12-31 | -$1.09M 10-Q · filed 2015-02-17 | -$3.11M derived: sum of 2 quarters · filed 2015-02-17 | -$7.66M 10-Q · filed 2015-02-17 | -$9.49M derived: sum of 4 quarters · filed 2015-02-17 | ||
| 2014-09-30 | -$2.02M 10-Q · filed 2014-11-19 | -$6.57M 10-Q · filed 2014-11-19 | -$8.40M derived: sum of 3 quarters · filed 2014-11-19 | -$8.27M derived: sum of 4 quarters · filed 2015-02-17 | ||
| 2014-06-30 | -$4.55M 10-Q · filed 2014-08-12 | -$6.38M derived: sum of 2 quarters · filed 2014-08-12 | -$6.25M derived: sum of 3 quarters · filed 2015-02-17 | -$7.71M derived: sum of 4 quarters · filed 2015-02-17 | ||
| 2014-03-31 | -$1.82M derived: 10-K 12 month − 10-Q 9 month · filed 2014-06-25 | -$1.69M derived: sum of 2 quarters · filed 2015-02-17 | -$3.15M derived: sum of 3 quarters · filed 2015-02-17 | -$2.97M 10-K · filed 2014-06-25 | -$70.64M 10-K · filed 2014-06-25 | |
| 2013-12-31 | $131.00K 10-Q · filed 2015-02-17 | -$1.33M derived: sum of 2 quarters · filed 2015-02-17 | -$1.14M 10-Q · filed 2015-02-17 | -$4.91M derived: sum of 4 quarters · filed 2015-02-17 | -$68.81M 10-Q · filed 2014-02-14 | |
| 2013-09-30 | -$1.46M 10-Q · filed 2014-11-19 | -$1.27M 10-Q · filed 2014-11-19 | -$5.04M derived: sum of 3 quarters · filed 2014-11-19 | -$10.38M derived: sum of 4 quarters · filed 2014-11-19 | -$68.94M 10-Q · filed 2013-11-14 | |
| 2013-06-30 | $185.70K 10-Q · filed 2014-08-12 | -$3.58M derived: sum of 2 quarters · filed 2014-08-12 | -$8.92M derived: sum of 3 quarters · filed 2014-08-12 | -$10.88M derived: sum of 4 quarters · filed 2014-08-12 | ||
| 2013-03-31 | -$3.77M derived: 10-K 12 month − 10-Q 9 month · filed 2014-06-25 | -$9.11M derived: sum of 2 quarters · filed 2014-06-25 | -$11.06M derived: sum of 3 quarters · filed 2014-06-25 | -$12.89M 10-K · filed 2014-06-25 | ||
| 2012-12-31 | -$5.33M 10-Q · filed 2014-02-14 | -$7.29M derived: sum of 2 quarters · filed 2014-02-14 | -$9.12M 10-Q · filed 2014-02-14 | |||
| 2012-09-30 | -$1.96M 10-Q · filed 2013-11-14 | -$3.78M 10-Q · filed 2013-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B |